- Company
- Reasonable compromise between industry-govt is key
- by Eo, Yun-Ho Dec 3, 2024 05:52am
- The pharmacoeconomic evaluation exemption system has received unflattering attention since its implementation. It is no wonder that the government has been gathering voices in support of its 'reduction' under the pretense of 'improvement'. The PE exemption system is the only system in Korea's insurance policy landscape that helps patients
- InterView
- ‘3 IBD treatment trends…early treatment is the first’
- by Kim, Jin-Gu Dec 2, 2024 05:49am
- The treatment method for a single disease can continue to change at a very fast pace. This is true for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. In recent years, a variety of drugs have been developed to treat these diseases, and the treatment trend is changing as more research is conducted. Dr. Ju
- Company
- Promotion of new drugs·biosimilars at KOS annual conference
- by Son, Hyung Min Dec 2, 2024 05:49am
- Korean and international pharmaceutical and biotech industries are fiercely competing for marketing in the market for macular degeneration. Global companies, including Novartis, Roche, and Bayer, and Korean pharmaceutical companies, including Kukje Pharm, Samil Pharm, and Chong Kun Dang, have participated in the annual meeting of the Korean
- Company
- Antibody drug 'Fasenra' lands in KOR with EGPA indication
- by Eo, Yun-Ho Dec 2, 2024 05:49am
- Astra Zeneca's Fasenra, an antibody drug for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), is expected to be introduced in South Korea. According to industry sources on November 29, Astra Zeneca Korea has recently submitted an application to the Ministry of Food and Drug Safety (MFDS) for an expanded indication of
- Company
- Industry speeds up the development of bispecific antibodies
- by Son, Hyung Min Dec 2, 2024 05:49am
- The Korean pharmaceutical industry is accelerating the clinical trials of bispecific antibodies to secure solid tumor indications. Bispecific antibodies, which have an additional specific antigen binding site compared to monoclonal antibodies, are recognized for their clinical benefits. GC Biopharma, Hanmi Pharmaceutical, ABL Bio, and Immuneonci
- Company
- Is RWD needed for post-listing control of PE exempt drugs?
- by Eo, Yun-Ho Dec 2, 2024 05:49am
- The budget is tight, but the use of high-priced drugs continues to rise. The government is beginning to feel the strain of the systems it has put in place to increase access to new drugs, especially the pharmacoeconomic evaluation (PE) exemption system, which is increasingly being utilized and being subject to criticism. "The purpose of
- Company
- oHCM drug 'Camzyos' gets greenlight for reimb
- by Eo, Yun-Ho Nov 29, 2024 05:55am
- 'Camzyos,' a new drug to treat obstructive hypertrophic cardiomyopathy (oHCM), will finally be listed for reimbursement. The Ministry of Health and Welfare (MOHW) held the 23rd Health Insurance Policy Review Committee meeting on November 28, announcing that BMS Korea’s Camzyos (mavacamten), a new drug used to treat obstructive hypertroph
- Company
- Deregulate to foster new modalities like ADC, gene therapy
- by Son, Hyung Min Nov 29, 2024 05:55am
- New modalities (therapeutic approaches) such as antibody-drug conjugates (ADCs), obesity drugs, and gene-editing technologies need dramatic regulatory relief to settle in Korea, said experts. On the 14th, KoreaBio held a seminar on trends and prospects of the bio-industry at the El Tower in Seocho-gu, Seoul. At the event, Seung-Kyou Lee,
- Company
- Samsung Bioepis names Kyung-Ah Kim as new CEO
- by Nov 29, 2024 05:55am
- Samsung Bioepis has changed its CEO for the first time since its launch. Kyung-ah Kim (56), Executive Vice President and Development Division Leader, has been appointed as CEO. This is the first female CEO appointed in the Samsung Group. Hansung Ko, who has served as CEO for 12 years since the launch of Samsung Bioepis, will take over as h
- Company
- 'Global obesity drug market 79 times bigger than Korea'
- by Son, Hyung Min Nov 29, 2024 05:55am
- Multinational pharmaceutical companies have been achieving significant growth through a strategy that focuses on core industries and key therapeutic areas (TA)s. On the 14th, KoreaBIO held a seminar on trends and prospects of the bio-industry at Yangjae El Tower. On this day, Kang-Bok Lee, Marketing & Sales Excellence Lead at IQVIA, shar
